The latest update is out from Microbot Medical ( (MBOT) ).
On February 25, 2025, Microbot Medical announced a significant milestone in its collaboration with Corewell Health, demonstrating the feasibility of using its LIBERTY® Endovascular Robotic System for remote coronary simulation procedures. This research, accepted for presentation at the Cardiovascular Research Technologies annual meeting, highlights the potential of robotic telesurgery to enhance healthcare access, although the telesurgery feature is still under development and not yet FDA approved.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on improving global healthcare quality. It has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to break traditional barriers to advanced robotic systems.
YTD Price Performance: 36.84%
Average Trading Volume: 4,015,351
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $54.2M
See more insights into MBOT stock on TipRanks’ Stock Analysis page.